Accumulate, Hold for Long term

Excellent Opportunity to buy the stock. Strides revenues in Q4FY21 grew by 47% YoY to Rs.908 cr during the quarter with sales growth in the regulated markets and emerging markets.

I have entered around the 770 mark as Investment and plan to hold for long term

Chart study, not a call
Fundamental Analysislong-termstridespharmaTrend Analysis

Disclaimer